Printed From:

PRALUENT® (alirocumab) Administration

Easy-to-use, prefilled PRALUENT pen1-3

Same device, regardless of the dose, available in 2 different strengths1

Administered every 2 weeks or once monthly based on individual patient preference

75 mg & 150 mg

are administered with a single subcutaneous 1-mL injection every 2 weeks*

300 mg

monthly dose is administered as 2 consecutive, subcutaneous 150-mg injections at 2 different injection sites every 4 weeks

If needed, patients may keep PRALUENT at room temperature up to 77°F (25°C) for a maximum of 30 days in original carton to protect from light

The pen is not made with natural rubber latex

*The recommended starting dose is 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage.1

PRALUENT offers a once-monthly dosing option with 2 injections, each delivered in up to 20 seconds

Patients self-injected at home with confidence and convenience3†

were confident in their ability to self-inject

found the injection convenient to use

Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in the PRALUENT randomized clinical trial program (ODYSSEY). The I-TAQ is a 22-item, self-administered questionnaire, developed as a measure of injection-treatment acceptance for use in patients who inject their medications via subcutaneous injections.3


Learn more about flexible dosing options from a PRALUENT Field Representative

Contact a rep


  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.
  2. Roth EM, Bujas-Bobanovic M, Louie MJ, Cariou B. Patient and physician perspectives on mode of administration of the PCSK9 monoclonal antibody alirocumab, an injectable medication to lower LDL-C levels. Clin Ther. 2015;37:1945-1954.
  3. Tatlock S, Arbuckle R, Sanchez R, et al. Psychometric evaluation of a treatment acceptance measure for use in patients receiving treatment via subcutaneous injection. Value Health. 2017;20:430-440.


Learn how MyPRALUENT® Patient Services can support your patients

Get support


Get help with prior authorization, coverage information, and more

Learn how